Alnylam Pharmaceuticals (NASDAQ:ALNY) stockholders approved all board-recommended proposals at the company’s 2026 annual meeting, including the election of three Class I directors, an advisory vote on executive compensation and the ratification of PricewaterhouseCoopers LLP as the company’s independent auditor for fiscal 2026.
Amy Schulman, chair of the board, opened the virtual meeting and introduced the company’s directors and senior management team. Bryan Supran, Alnylam’s chief legal officer and corporate secretary, conducted the formal portion of the meeting.
Stockholders Approve Board Proposals
The three Class I director nominees elected to three-year terms were Stuart A. Arbuckle, Dr. Yvonne Greenstreet and Dr. Elliott Sigal. Greenstreet is also Alnylam’s chief executive officer.
Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. In addition, they ratified the appointment of PricewaterhouseCoopers LLP as Alnylam’s independent auditor for the fiscal year ending Dec. 31, 2026.
Supran said preliminary voting results showed that a majority of votes cast supported each proposal. He added that final results would be reported in a Form 8-K to be filed with the Securities and Exchange Commission within four business days.
After the formal business concluded, Josh Brodsky, vice president of investor relations, said there were no stockholder questions related to meeting matters.
Company Highlights Commercial Momentum
Following the formal meeting, Brodsky delivered a brief company update, noting that the presentation included forward-looking statements and that actual results could differ materially from those statements.
Brodsky said Alnylam has “a unique profile in the biotech industry,” citing its RNA interference, or RNAi, platform, commercial execution and pipeline. He said the company has more than 25 programs in active clinical development and six Alnylam-invented medicines on the market, which are generating multibillion-dollar annual revenue streams and treating hundreds of thousands of patients globally.
The company reported that its first quarter marked its first period exceeding $1 billion in product revenue. Brodsky said Alnylam delivered $1.036 billion in combined net product revenues, up 121% year over year and 4% compared with the fourth quarter of 2025.
Within its TTR franchise, Brodsky said global TTR net revenues reached $910 million in the first quarter, up 6% from the fourth quarter and 153% year over year. He said AMVUTTRA continued to show momentum one year into the ATTR cardiomyopathy launch.
Brodsky said the company remained confident in its 2026 TTR revenue guidance and continued to expect more substantial quarter-over-quarter growth in TTR revenues in the U.S. and internationally over the balance of the year.
AMVUTTRA Launch and TTR Strategy
Brodsky pointed to several elements supporting AMVUTTRA’s launch, including physician preference, patient access and the provider network. He said more than 90% of patients are covered with first-line access and that most pay no out-of-pocket costs. He also said about 90% of U.S. patients can access AMVUTTRA within about 10 miles of their home.
He identified three indicators the company is watching for continued launch success:
- Expansion of the prescriber base, including more than 1,200 new U.S. prescribers since the cardiomyopathy launch;
- Continued growth in the ATTR-CM category, which Brodsky said remains significantly underdiagnosed and undertreated;
- Adherence and persistence, supported by quarterly dosing.
Brodsky said Alnylam estimates there are 200,000 ATTR-CM patients in the U.S. and that more than 80% remain untreated. He said the company is pursuing AI-enabled partnerships aimed at facilitating earlier diagnosis and treatment.
2026 Guidance and Pipeline Goals
Brodsky reiterated Alnylam’s 2026 net product revenue guidance, saying the company expects total combined product sales of $4.9 billion to $5.3 billion. That outlook includes TTR franchise guidance of $4.4 billion to $4.7 billion, representing 83% growth at the midpoint, according to the company.
On the pipeline, Brodsky said Alnylam expects four clinical data readouts in 2026. He also said the company is advancing three Phase III studies, planning to initiate three Phase II studies and file three to four new investigational new drug applications.
Brodsky also summarized Alnylam’s five-year goals under its “Alnylam 2030: Accelerating Innovation, Scaling Impact” plan. He said the company aims to lead the TTR market in revenue by 2030 and cumulatively across the five-year period. The company also plans to launch nucresiran, described by Brodsky as a next-generation TTR silencer, first in polyneuropathy by the end of 2028 and then in cardiomyopathy by the end of 2030.
Beyond TTR, Brodsky said Alnylam aims to deliver two or more transformative medicines with blockbuster potential, expand RNAi delivery to 10 tissue types and build a pipeline of more than 40 clinical programs. He said the company plans to invest about 30% of revenue in non-GAAP research and development.
Under its financial targets, Brodsky said Alnylam aims to achieve at least a 25% total revenue compound annual growth rate through the end of 2030 and an approximately 30% non-GAAP operating margin across the period.
About Alnylam Pharmaceuticals (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
